Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out at Oncology Injectable Formulation Facility at Panelav during the period from 4-14th October, 2022.

This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA. The company had also started receiving ANDA approval manufactured at this facility.

Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5,000 are well recognized by doctors and patients.